Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Arribas

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
The Science of the Total Environment|July 15, 2024
Kinetics and toxicity of nanoplastics in ex vivo exposed human whole blood as a model to understand their impact on human healthJ Arribas Arranz, A Villacorta, L Rubio, et al.
Oncogene|October 27, 2009
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthS Chandarlapaty, M Scaltriti, P Angelini, et al.
Zootaxa|October 22, 2014
Review of the systematics, distribution, biogeography and natural history of Moroccan amphibiansWouter Beukema, Philip De Pous, David Donaire-Barroso, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
Hematological Oncology|March 5, 2025
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC SubtypeChiara Tarantelli, Omar Kayali, Elisa Civanelli, et al.
British Journal of Haematology|September 18, 2025
Comprehensive analysis of <sup>177</sup>Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemesSebastian Patzke, Luciano Cascione, Katrine B Melhus, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 23, 2013
Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profilingAlberto J Arribas, Cristina Gómez-Abad, Margarita Sánchez-Beato, et al.
Revista De Gastroenterologia De Mexico|November 30, 2016
Evaluation of the efficacy of therapeutic endoscopy in gastrointestinal bleeding secondary to angiodysplasiasJ Arribas Anta, C Zaera de la Fuente, R Martín Mateos, et al.
Haematologica|January 26, 2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agentsChiara Tarantelli, Lu Zhang, Elisabetta Curti, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
The Science of the Total Environment|July 15, 2024
Kinetics and toxicity of nanoplastics in ex vivo exposed human whole blood as a model to understand their impact on human healthJ Arribas Arranz, A Villacorta, L Rubio, et al.
Oncogene|October 27, 2009
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthS Chandarlapaty, M Scaltriti, P Angelini, et al.
Zootaxa|October 22, 2014
Review of the systematics, distribution, biogeography and natural history of Moroccan amphibiansWouter Beukema, Philip De Pous, David Donaire-Barroso, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
Hematological Oncology|March 5, 2025
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC SubtypeChiara Tarantelli, Omar Kayali, Elisa Civanelli, et al.
British Journal of Haematology|September 18, 2025
Comprehensive analysis of <sup>177</sup>Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemesSebastian Patzke, Luciano Cascione, Katrine B Melhus, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 23, 2013
Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profilingAlberto J Arribas, Cristina Gómez-Abad, Margarita Sánchez-Beato, et al.
Revista De Gastroenterologia De Mexico|November 30, 2016
Evaluation of the efficacy of therapeutic endoscopy in gastrointestinal bleeding secondary to angiodysplasiasJ Arribas Anta, C Zaera de la Fuente, R Martín Mateos, et al.
Haematologica|January 26, 2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agentsChiara Tarantelli, Lu Zhang, Elisabetta Curti, et al.
Pageof 12